Signal from the log
Abcuro
$66M · United States
Abcuro obtient 66 M$ pour financer la phase 3 de son anticorps dans une maladie musculaire invalidante, la myosite à inclusions. Le Form D de la société montre 39,4 M$ réellement placés sur 176,5 M$ autorisés.
Spotted Amount read from the headline
Announced on , logged by the watch of 7 August 2026.
- Operation
- Funding round
- Announced amount
- $66M
- Country
- United States
What the log says
Editorial note, in French
Dépôt réglementaire repéré à la SEC. Le tour n'est pas encore documenté publiquement, aucun fonds n'y est nommé.
- No fund is publicly named. It is the first condition of the selection bar: without a named investor there is no round to tell.
- The amount shown is an automatic reading of the source headline, not a reading of the press release. It is not verified yet.
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.